These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32871794)

  • 1. VEGF-A Is Associated With the Degree of TILs and PD-L1 Expression in Primary Breast Cancer.
    Fujii T; Hirakata T; Kurozumi S; Tokuda S; Nakazawa Y; Obayashi S; Yajima R; Oyama T; Shirabe K
    In Vivo; 2020; 34(5):2641-2646. PubMed ID: 32871794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer.
    Hirakata T; Fujii T; Kurozumi S; Katayama A; Honda C; Yanai K; Tokuda S; Nakazawa Y; Obayashi S; Yajima R; Kaira K; Oyama T; Shirabe K
    Breast Cancer Res Treat; 2020 Jun; 181(2):331-338. PubMed ID: 32253685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.
    Li Y; Opyrchal M; Yao S; Peng X; Yan L; Jabbour H; Khoury T
    Breast Cancer Res Treat; 2018 Jul; 170(2):293-302. PubMed ID: 29524062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.
    Pelekanou V; Carvajal-Hausdorf DE; Altan M; Wasserman B; Carvajal-Hausdorf C; Wimberly H; Brown J; Lannin D; Pusztai L; Rimm DL
    Breast Cancer Res; 2017 Aug; 19(1):91. PubMed ID: 28784153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of programmed death ligand-1 (PD-L1) and tumor infiltrating lymphocytes (TILs) in breast carcinoma and their clinical significance.
    Mondal SK; Bhattacharya S; Sarkar AP; Saha R
    J Cancer Res Ther; 2023 Apr; 19(Supplement):S81-S86. PubMed ID: 37147987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.
    Kurozumi S; Fujii T; Matsumoto H; Inoue K; Kurosumi M; Horiguchi J; Kuwano H
    Med Mol Morphol; 2017 Dec; 50(4):185-194. PubMed ID: 28936553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
    Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S
    Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value.
    Kim A; Lee SJ; Kim YK; Park WY; Park DY; Kim JY; Lee CH; Gong G; Huh GY; Choi KU
    Sci Rep; 2017 Sep; 7(1):11671. PubMed ID: 28916815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
    Zhang L; Wang XI; Ding J; Sun Q; Zhang S
    Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer.
    Zhu X; Zhang Q; Wang D; Liu C; Han B; Yang JM
    Cancer Biol Ther; 2019; 20(8):1105-1112. PubMed ID: 30929569
    [No Abstract]   [Full Text] [Related]  

  • 13. Genomic alterations affecting tumor-infiltrating lymphocytes and PD-L1 expression patterns in triple-negative breast cancer.
    Wang H; Ding XH; Liu CL; Xiao Y; Shui RH; Li YP; Chen C; Yang WT; Liu S; Chen CS; Shao ZM; Jiang YZ
    J Natl Cancer Inst; 2023 Dec; 115(12):1586-1596. PubMed ID: 37549066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 and TILs expression and their association with clinicopathological characteristics in Vietnamese women with primary invasive breast cancer.
    Huynh CG; Huynh NX; Truong HBT; Thai TT; Doan TPT
    Medicine (Baltimore); 2023 Jun; 102(26):e34222. PubMed ID: 37390260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of CD20+ B cells and PD-L1+ immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients.
    Arias-Pulido H; Cimino-Mathews AM; Chaher N; Qualls CR; Joste N; Colpaert C; Marotti JD; Chamberlin MD; Foisey MG; Prossnitz ER; Emens LA; Fiering S
    Breast Cancer Res Treat; 2021 Dec; 190(3):477-489. PubMed ID: 34542773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed death ligand 1 (PD-L1) in colon cancer and its interaction with budding and tumor-infiltrating lymphocytes (TILs) as tumor-host antagonists.
    Lang-Schwarz C; Melcher B; Hartmann A; Bertz S; Dregelies T; Lang-Schwarz K; Vieth M; Sterlacci W
    Int J Colorectal Dis; 2021 Nov; 36(11):2497-2510. PubMed ID: 34170390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of tumor-infiltrating lymphocytes, PD-L1, and
    Reznitsky FM; Jensen JD; Knoop A; Jensen MB; Laenkholm AV
    Acta Oncol; 2023 Dec; 62(12):1913-1920. PubMed ID: 37961947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).
    Farrag MS; Abdelwahab K; Farrag NS; Elrefaie WE; Emarah Z
    J Egypt Natl Canc Inst; 2021 Jul; 33(1):16. PubMed ID: 34241710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of tumor PD-L1 expression combined with CD8
    Wang Q; Lou W; Di W; Wu X
    Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological values of PD-L1 expression in HER2-positive breast cancer.
    Kurozumi S; Inoue K; Matsumoto H; Fujii T; Horiguchi J; Oyama T; Kurosumi M; Shirabe K
    Sci Rep; 2019 Nov; 9(1):16662. PubMed ID: 31723167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.